Frontida BioPharm has made an equity investment in Oncoceutics as part of a product development and commercialization agreement to advance the company's lead compound.
Jerusalem, Israel-based drugmaker Oramed Pharmaceuticals has been granted patent approval for its oral insulin technology by the Japanese Patent office.
BioFocus and Activiomics have teamed up to offer a drug discovery and biomarker service which it says will improve the identification of novel targets.
Advinus Therapeutics is to use Corning Epic label-free detection to provide clients in India and abroad with biologically relevant drug discovery data.
DiscoveRx has added GPCR platforms to its portfolio, enhancing its ability to provide information on a compound’s mode of action, activated receptor recycling and efficacy in animal models.
Contract research company ChanTest has acquired fellow US firm Applied Clinical Sciences, a specialist in the development of drugs that affect G-protein coupled receptors (GPCR), one of the most fertile areas of drug discovery.
Tocris Bioscience has launched a new search facility that enables researchers to search for chemicals by the biological targets they work on, rather than the chemical name itself.
Caliper Life Sciences has launched two new kinase profiling services as well as new assay kits that aim to provide researchers with a better understanding of their kinase inhibitor drug candidates.
Redpoint Bio has been issued with a patent for an assay technology
which tests whether a compound enhances or inhibits the bitter or
sweet taste of different ingredients, allowing the company to
screen for flavour enchancing compounds.
US firms Multispan and Promega have paired up to develop assay
tools for G-protein coupled receptor (GPCR) screening, in the hope
of speeding up drug discovery on these, the most popular protein
targets in pharma.
In the inevitable reshuffle that comes after a major acquisition,
Bayer's healthcare division has today announced plans to cut 30 per
cent of its drug pipeline.
BioFocus DPI has released a new informatics system that can combine
chemical and biological data from various sources to optimise
protein kinase inhibitor candidate selection.
ActivX has launched a new profiling platform, which the company
claims allows the functional analysis of twice the number of
protein kinases than competing systems.
The second in a series of periodic roundups of drugs that have
moved from preclinical research into clinical testing via the
announcement of a Phase I trial or an application for a trial to
industry regulators.
PerkinElmer (PE) has continued its growth in the advanced cellular
sciences sector, with the completed acquisitions of Euroscreen
Products and Evotec Technologies.
Millipore has now made available its GPCRProfiler screening service
that allows more accurate characterisation of lead compounds
enabling pharmaceutical and biotechnology companies to accelerate
their lead optimisation efforts.
According to a new report, the kinase-targeted drug market is set
to grow from $12.7 bn (€10bn) in 2005 to $58.6bn in 2010. Cancer
(mainly solid tumours) is expected to remain the dominant
application throughout the forecast period.
UK drug discovery company, Peakdale Molecular, has introduced its
collection of drug-like molecules targeted towards specific
receptor families achieving drug selectivity to modulate
therapeutically relevant signalling pathways.
A team of scientists believe that a worm can help to discover new
drugs by genetically modification allowing the worm to distinguish
harmful chemicals to those with therapeutic benefit.
Locus Pharmaceuticals has announced it has entered a drug discovery
agreement with Ono Pharmaceuticals in a deal that will focus on
protein kinases as a molecular target.
Sigma-Aldrich introduces its signal transduction protein array for
high-throughput functional screening, which is set to play a major
role in identifying proteins that are involved in cellular
processes including proliferation, differentiation...
Cisbio has introduced its second IP-One assay, which can be used by
all laboratories focused on GPCR-based targets of which 45 per cent
of currently marketed drugs owe their efficacy to.
A new study has suggested a new approach to drug design, which
recommends that a loose fit may be the best fit especially when
producing drugs for thyroid related conditions.
Drug discovery outfit, Tripos, has announced details of a
collaboration with Abbott, which is to concentrate on chemical
design and synthesis in a deal that mirrors, those announced
earlier in Q1 with Genzyme, GSK Research and Development...
A newly discovered process that explains how the body's nervous
system relays information, may depend on how "wet" the "kiss" is
when one neuron fires a packet of neurotransmitter across a synapse
to a receptive...
Scientists have synthesised a lab-made version of a human protein,
which alleviates symptoms of both acute and chronic arthritis. The
study opens new research avenues to better understand and develop
drug treatments for rheumatoid...
A newly discovered compound, which has revealed new links between
cell signalling pathways and cell migration, may suggest new
avenues for novel pharmaceutical therapies for treating a variety
of diseases, including cancer.
Euroscreen has announced the issuance of a US patent, which covers
the use of a human G-protein-coupled receptor (GPCR) human P2Y13.
The patent protects screening processes using this receptor to find
compounds that modulate its activity,...
Tripos introduces its LeadDiscovery program to accelerate the drug
discovery process. The new program offers a method to develop novel
preclinical compounds for customers in the pharmaceutical and
biotechnology industry.
Peakdale Molecular launches its latest G-Protein Coupled Receptor
(GPCR) library, specifically designed to synthesise and
characterise for screening against aminergic GPCR targets.
BioFocus and Organon have announced they are to embark on the
second phase of collaborative projects involving key GPCR targets
for therapeutic applications and drug discovery.
Sigma-Aldrich has launched a handful of laboratory equipment and
technological developments that could prove useful in drug
discovery. The life science company is currently in the midst of a
reorganisation of its operating structure...
Serologicals company, Upstate Group, has introduced a one-of-a-kind
service, which aims to provide drug development companies with
valuable insights into therapies and efficacy within cells.
Medical diagnostics company Fujirebio is to combine its microarray
platform with Carna Biosciences to create a series of new products
for kinase studies.
Cellomics has launched a new image analysis software module that
allows scientists performing drug discovery and basic science
research to analyse a broad variety of cell-based assays in as
little as five minutes.
Cellomics has launched a new image analysis software module that
allows scientists performing drug discovery and basic science
research to analyse a broad variety of cell-based assays in as
little as five minutes.
A novel, non-radioactive, quantitative cell-based assay, which uses
the In-Cell Western technique, has determined the functional
potency of agonists and antagonists for D2 and D3 receptors,
allowing drug researchers to quantify multiple...
The European Union has granted nearly €25 million to two
large-scale research projects coordinated by the University of
Helsinki in the area of protein kinases, a promising class of new
drug targets.
A new drug target, which blocks the reproduction of cancerous cells
without the side effects commonly associated with existing cancer
drugs, has been discovered by scientists who believe this target is
linked to other diseases including...
Drug discovery company Ablynx is to enter into a partnership with
Proctor and Gamble Pharmaceuticals. The agreement will make use of
Ablynx's Nanobody platform to develop drug candidates against a
G-protein coupled receptor (GPCR)...
It has been eight years since Molecular Devices first introduced
its FLIPR (Fluorometric Imaging Plate Reader) onto the market to
answer the need for a detection device that could handle cells.
Researchers studying cell migration and the screening of drug
compounds, can benefit from a new type of cell analysis system
developed by Guava Technologies. These processes are extensively
studied in cancer research and drug discovery...
Two British firms, De Novo Pharmaceuticals and Peakdale Molecular,
are to enter into a joint collaboration to exploit their respective
skills in molecular design and chemistry synthesis, writes market
analysts Datamonitor this week.
